MPP Inks Deals With 27 Generics Makers to Produce Merck’s COVID-19 Pill
The United Nations-backed Medicines Patent Pool (MPP) has secured agreements with 27 generics makers in Asia and Africa to supply Merck’s COVID-19 oral antiviral, molnupiravir, in 105 low- and middle-income countries.
In October 2021, Merck signed a voluntary licensing deal allowing the MPP to negotiate agreements with local generics manufacturers in order to expand access to its COVID-19 pill, co-developed with Ridgeback Biotherapeutics.
Under that MPP-Merck pact, neither Merck nor Ridgeback is allowed to accept any royalties on sales for as long as the World Health Organization considers COVID-19 a public health emergency.
https://www.fdanews.com/
